



Venus Medtech (Hangzhou) Inc.
杭州启明醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代號: 2500)

NOTIFICATION LETTER

April 30, 2024

Dear Registered Shareholders,

Venus Medtech (Hangzhou) Inc. (the "Company")
– Notice of Publication of 2023 Annual Report (the "Current Corporate Communications")

The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong Limited ("HKEX") at www.hkexnews.hk and the Company's website at www.venusmedtech.com. If you have any difficulty in receiving or gaining access to the Current Corporate Communications posted on the Company's website for any reason, please send your request (specifying your name, address and request) by email at venusmedtech.ecom@computershare.com.hk or by notice in writing to the Company's H share registrar (the "H Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong. The Company will promptly upon receipt of your request send the Current Corporate Communications to you in printed form free of charge.

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023 and the Articles of Association of the Company, the Company is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.venusmedtech.com and the HKEX website at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

The Company will send the Actionable Corporate Communications to its Shareholders individually in electronic form by email. To ensure timely receipt of the Actionable Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the H Share Registrar.

If you are a new registered shareholder and the Company does not receive the duly completed and signed Reply Form or any response in writing indicating any objection from you by May 15, 2024, and until you inform the H Share Registrar, you are deemed to have consented to read all future Corporate Communications published on the website of the Company at www.venusmedtech.com (the "Website Version"), and a notification of the publication of the Corporate Communications on the Company's website will be sent to you in the future.

If you elect to receive the Website Version of future Corporate Communications, you are requested to provide an email address in the Reply Form for the purpose of receiving all future Actionable Corporate Communications in electronic form from the Company. If no valid and functional email address is provided by you in the Reply Form or if you are otherwise deemed to have consented to receive the Website Version of future Corporate Communications, the Company will send to you by post at your address as appearing in the Company's register of members maintained by the H Share Registrar, (i) a notification letter for the publication of Corporate Communications on the website of the Company and (ii) all future Actionable Corporate Communications in printed form, until such time when you have provided a valid and a functional email address to the H Share Registrar for receiving the same.

If you want to receive future Corporate Communications in printed form, please complete the Reply Form on the reverse side and send it to the H Share Registrar or send an email to venusmedtech.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the H Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
By order of the Board
Venus Medtech (Hangzhou) Inc.
Mr. Lim Hou-Sen (Lin Haosheng)
Executive Director

Note: Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including, but not limited to, (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) notices of meeting; (d) listing documents; (e) circulars; and (f) proxy forms. Pursuant to Rule 1.01 of the Listing Rules, Actionable Corporate Communications are any corporate communications that seek instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.



Venus Medtech (Hangzhou) Inc.
杭州啓明醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)
(Stock Code 股份代號: 2500)

通知信函

各位登記股東：

杭州啓明醫療器械股份有限公司（「本公司」） – 2023 年度報告（「本次公司通訊文件」）之發布通知

本公司的本次公司通訊文件備有中、英文版本，並已上載於香港聯合交易所有限公司（「香港交易所」）網站（www.hkexnews.hk）及本公司網站（www.venusmedtech.com），歡迎瀏覽。閣下若因任何理由以致在收取或接收載於本公司網址上的本次公司通訊文件出現困難，閣下可將要求（註明閣下的姓名、地址及要求）以電郵方式發送到本公司之電郵地址 venusmedtech.ecom@computershare.com.hk 或以書面方式郵寄致本公司的 H 股股份過戶登記處（「H 股股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。本公司將於接到閣下通知後，盡快向閣下免費發送有關本次公司通訊文件的印刷本。

以電子方式發布公司通訊之安排

根據香港聯合交易所有限公司證券上市規則第 2.07 條（「上市規則」）已於 2023 年 12 月 31 日起生效的擴大無紙化制度及以電子方式發布公司通訊規定下，以及本公司的組織章程細則，本公司謹此通知閣下，本公司已採用以電子方式發布公司通訊（「公司通訊」）之安排，該公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於 (a) 董事會報告、年度賬目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及其中期報告摘要（如適用）；(c) 會議通知；(d) 上市文件；(e) 通函和 (f) 代表委任表格。

請注意，所有日後公司通訊的英文版和中文版將在本公司網站 www.venusmedtech.com 及香港交易所網站 www.hkexnews.hk 上提供，以代替印刷本。

徵集電子聯絡資料

本公司將以電子通訊方式（通過電子郵件）向股東個別地發送可供採取行動的公司通訊。為確保及時收到可供採取行動的公司通訊，本公司建議閣下透過掃描隨附之回條（「回條」）上列印的閣下專屬二維碼來提供閣下的電子郵件地址。或者，閣下也可以簽署回條並交回 H 股股份過戶處香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

倘若閣下為本公司的新登記股東及本公司於二零二四年五月十五日之前尚未收到閣下已填妥並簽署之回條或表示反對之任何書面回覆，閣下將被視為已同意瀏覽於本公司網站 www.venusmedtech.com（「網上版本」）上的所有公司通訊，而公司日後將向閣下發送已在公司網站登載的公司通訊之通知。

如閣下選擇接收日後公司通訊的網上版本，閣下需要在回條中提供電郵地址，以便接收本公司日後以電子形式發布的所有可供採取行動的公司通訊。若閣下在回條中沒有提供有效且可用的電郵地址，或閣下被視為已同意接收日後公司通訊的網上版本，本公司將根據 H 股股份過戶處所存置的股東名冊上所示的地址透過郵寄方式向閣下發送 (i) 在本公司網站上發布公司通訊的通知函及 (ii) 所有日後可供採取行動的公司通訊的印刷本，直至閣下向 H 股股份過戶處提供有效且可用的電郵地址以接收該等公司通訊。

若閣下希望收取日後公司通訊之印刷本，請填妥回條或發送電子郵件至 venusmedtech.ecom@computershare.com.hk，並註明閣下的姓名、地址以及收取公司通訊印刷本的要求。請注意，收取未來公司通訊印刷本之指示由收悉閣下指示當日起計一年內有效，此後將過期。

如閣下對本函件有任何疑問，請於辦公時間星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正（香港時間）其間致電 H 股股份過戶處 (852) 2862 8688 查詢。

承董事會命
杭州啓明醫療器械股份有限公司
執行董事
林浩昇先生
謹啟

二零二四年四月三十日

附註：公司通訊乃指本公司發出或將予發出以供其任何證券持有人參照或採取行動的任何文件，其中包括但不限於：(a) 董事會報告、年度賬目連同核數師報告的副本以及（如適用）財務摘要報告；(b) 中期報告及（如適用）中期摘要報告；(c) 會議通告；(d) 上市文件；(e) 通函；及 (f) 代表委任表格。根據上市規則第 1.01 條，「可供採取行動的公司通訊」指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。



REPLY FORM 回條

To: **Computershare Hong Kong Investor Services Limited**
(The “H Share Registrar”)
17M Floor, Hopewell Centre
183 Queen’s Road East, Wanchai, Hong Kong

致： **香港中央證券登記有限公司**
(「H 股股份過戶處」)
香港灣仔皇后大道東 183 號
合和中心 17M 樓

(Please **choose ONLY ONE** of the options below)
(請從以下選項中**只選擇其中一項**)

<p>Option 1: Provide your email address for receipt of future Actionable Corporate Communications^(Note 3) of the Company via electronic dissemination by scanning your personalized QR code</p> <p>選項 1: 掃瞄 閣下專屬二維碼提供 閣下之電子郵件地址，以接收公司通過電子方式發佈可供採取行動的未來公司通訊^(附註 3)</p> <p>You are NOT required to return this Reply Form if you choose Option 1. 如選擇了選項 1，閣下無須交回本回條。</p>	<p>Personalized QR Code 專屬二維碼</p>
--	--

<p>Option 2: I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications^(Note 3) of the following listed company (the “Company”) via electronic dissemination</p> <p>選項 2: 本人/吾等現以書面提供本人/吾等之電子郵件地址，以確保收到以下上市公司（「公司」）通過電子方式發佈可供採取行動的未來公司通訊^(附註 3)</p> <p>Name of Securities holder(s) 證券持有人姓名： _____</p> <p>Name of the listed company 上市公司名稱： Venus Medtech (Hangzhou) Inc. 杭州啓明醫療器械股份有限公司</p> <p>Email address 電郵地址：^(Note 3 / 附註 3) <table border="1" style="width: 100%; height: 20px; margin-top: 5px;"> <tr> <td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td><td style="width: 10%;"> </td> </tr> </table> </p>													

<p>Option 3: I/we hereby request for receipt of Corporate Communications* in printed form (Please mark “✓” in the below box if applicable)</p> <p>選項 3: 本人/吾等現要求收取公司通訊*印刷版（如適用，請在以下方格內劃上「✓」號）</p> <p><input type="checkbox"/> receive future Corporate Communications* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction. ^(Note 5) 收取未來公司通訊*的印刷本，並已知悉本指示由收取指示日期起計一年內有效。^(附註 5)</p>	
--	--

Signature(s): ^(Note 1) 簽名： ^(附註 1) _____	Contact number: 聯絡電話號碼： _____	Date: 日期： _____
--	----------------------------------	--------------------

Notes 附註:

1. Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.
請清楚填妥 閣下之所有資料。如屬聯名股東，則本回條須由所有聯名股東聯合簽署，方為有效。
2. Any Reply Form with no signature or otherwise incorrectly completed will be void.
任何回條若未有簽署或在其他方面填寫不正確，則本回條將會作廢。
3. If the Company does not receive a functional email address in your reply, the Company will send the Actionable Corporate Communication in printed form in the future. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.
如公司沒有收到 閣下的有效電子郵件地址，本公司將以印刷本形式發送可供採取行動的未來公司通訊。可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利的公司通訊。
4. If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered.
如閣下通過二維碼、電郵、回條及/或其他方法提供多於一個的電子郵件地址，只有 閣下最後提供的電子郵件地址將會被用於登記。
5. If you mark “✓” in the box in Option 3, no email address will be registered and only Corporate Communications* in printed form will be received.
如 閣下在選項 3 方格內劃上「✓」號，將不會有電子郵件地址被登記，只有公司通訊*的印刷版會被收取。
6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.
為免存疑，在本回條上的任何額外指示，公司將不予處理。

* Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form.
除非另有註明，公司通訊乃公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

(i) “Personal Data” in this statement has the same meaning as “personal data” in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong (“PDPO”).
本聲明中所指的「個人資料」與香港法例第 486 章《個人資料（私隱）條例》（「《私隱條例》」）中「個人資料」的定義相同。

(ii) Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company’s electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.
閣下於本回條所提供的個人資料將用於（包括但不限於）有關公司以電子方式發布公司通訊及就 閣下持有的公司證券有關的其他事宜上與 閣下聯絡。閣下是自願向本公司提供個人資料，若 閣下未能提供足夠資料，本公司可能無法處理 閣下在本回條上所提的指示及/或要求。

(iii) Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the H Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
公司可就任何所說明的用途或在法例規定的情況下，將 閣下的個人資料披露或轉移給公司的附屬公司、H 股股份過戶處、及/或其他公司或團體，並將保留該等個人資料作核實及紀錄用途。

(iv) You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the H Share Registrar at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong or by email at PrivacyOfficer@computershare.com.hk.
閣下有權根據《私隱條例》的條文查詢及/或修改 閣下的個人資料。任何該等查詢及/或修改個人資料的要求均須以書面方式郵寄至 H 股股份過戶處（地址為香港灣仔皇后大道東 183 號合和中心 17M 樓）向香港隱私主任提出，或發送電郵至 PrivacyOfficer@computershare.com.hk。

<p>Mailing Label 郵寄標籤</p> <p>Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼: 37 Hong Kong 香港</p>

Please cut the mailing label and stick it on an envelope to return this form to us.
No postage is necessary if posted in Hong Kong.

當 閣下寄回此回條時，請將郵寄標籤貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。